Skip to main content

Table 2 Numbers, amyloid PET positive percentage, and plasma biomarkers in APOE ε4 carriers and non-carriers

From: Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease

APOE genotype

ε4 carriers

ε4 non-carriers

ε4 carriers (ε2ε4, ε3ε4, ε4ε4)

All ε4 non-carriers (ε2ε2, ε2ε3, ε3ε3)

ε4 carriers (ε2ε2, ε2ε3)

Amyloid PET+%

85.7%

26.3%

0

Plasma Aβ1–40 (pg/ml)

47.1 ± 7.2

50.9 ± 7.4

50.0 ± 8.5

Plasma Aβ1–42 (pg/ml)

17.9 ± 2.9

16.7 ± 2.9

16.5 ± 2.7

Plasma tau (pg/ml)

24.7 ± 9.9

19.3 ± 9.5*

18.8 ± 8.2

Plasma Aβ1–42/Aβ1–40

0.396 ± 0.117

0.343 ± 0.111

0.349 ± 0.126

Plasma Aβ1–42xtau (pg2/ml2)

468.2 ± 262.2

348.6 ± 242.1

331.0 ± 208.6

  1. Abbreviations: Amyloid β, PET positron emission tomography
  2. *P value < 0.05: ε4 carriers vs ε4 non-carriers